Letrozol Alter (Letrozole)

Letrozol Alter is an aromatase inhibitor indicated for hormone‑receptor‑positive breast cancer, acting on estrogen‑driven tumor pathways.

• Adjuvant therapy: reduces the risk of cancer recurrence after surgical removal of the primary tumor.
• Metastatic disease: slows progression of advanced breast cancer in postmenopausal patients.
• Neoadjuvant therapy: decreases tumor size before surgery to facilitate breast‑conserving procedures.

• Letrozole selectively inhibits the aromatase enzyme, which is responsible for converting adrenal and ovarian androgens into estrogens. By blocking this peripheral conversion, systemic estrogen levels decline, depriving estrogen‑dependent breast cancer cells of a growth stimulus and thereby inhibiting tumor proliferation.

Letrozol Alter may cause a range of adverse reactions. Patients should be monitored for both common and serious events.

Common Side Effects

• Hot flashes: sudden feeling of warmth and sweating.
• Joint pain: aching or stiffness in joints.
• Fatigue: persistent tiredness.
• Nausea: upset stomach or urge to vomit.
• Headache: mild to moderate cranial pain.
• Sweating: increased perspiration.

Serious or Rare Side Effects

• Severe liver injury: jaundice, elevated liver enzymes.
• Bone fracture: increased risk of osteoporosis‑related breaks.
• Pulmonary embolism: sudden shortness of breath or chest pain.
• Anaphylaxis: severe allergic reaction with swelling and difficulty breathing.
• Elevated cholesterol: significant rise in blood lipid levels.
• QT interval prolongation: potential cardiac arrhythmia.

Before initiating Letrozol Alter, clinicians should consider several safety measures.

• Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation.
• Liver function assessment: obtain baseline hepatic enzymes and repeat periodically.
• Cardiovascular risk evaluation: review history of thromboembolic events or uncontrolled hypertension.
• Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception.
• Drug interaction review: check for concurrent CYP3A4 inducers or estrogen‑containing products.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Letrozol Alter can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole plasma levels.
• Estrogen‑containing hormone therapy: antagonizes therapeutic effect.
• Antifungal agents that inhibit CYP3A4 (e.g., ketoconazole): may increase exposure and toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Selective serotonin reuptake inhibitors (SSRIs): potential additive effect on QT prolongation.